Orphan drugs in development for Huntington's disease: challenges and progress

References

• Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.
   PubMed Web of Science ®Google Scholar
• Kim SD, Fung VS. An update on Huntington’s disease: from the gene to the clinic. Curr Opin Neurol. 2014;27(4):477–483.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–983.
   Web of Science ®Google Scholar
• Perevozchikova T, Stanley CB, McWilliams-Koeppen HP, Rowe EL, Berthelier V. Investigating the structural impact of the glutamine repeat in huntingtin assembly. Biophys J. 15, 2014;107(2):411–421.
   Google Scholar
• Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest. 2011;121(2):476–483.
   Web of Science ®Google Scholar
• Tourette C, Li B, Bell R, et al. A large scale huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease. J Biol Chem. 2014;289(10):6709–6726.
   Web of Science ®Google Scholar
• Ratovitski T, Chighladze E, Arbez N, et al. Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell Cycle. 2012;11(10):2006–2021.
   PubMed Web of Science ®Google Scholar
• Burgunder JM. Recent advances in the management of choreas. Ther Adv Neurol Dis. 2013;6(2):117–127.
   Web of Science ®Google Scholar
• Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791–801.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31–42.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012;11(1):42–53.
   PubMed Web of Science ®Google Scholar
• Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A. 2005;102(16):5820–5825.
   PubMed Web of Science ®Google Scholar
• Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther. 2009;17(6):1053–1063.
   PubMed Web of Science ®Google Scholar
• Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest. 2011;121(2):500–507.
   Web of Science ®Google Scholar
• Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031–1044.
   PubMed Web of Science ®Google Scholar
• DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104(43):17204–17209.
   PubMed Web of Science ®Google Scholar
• Pfister EL, Kennington L, Straubhaar J, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington’s disease patients. Curr Biol. 2009;19(9):774–778.
   Web of Science ®Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19):8800–8805.
   PubMed Web of Science ®Google Scholar
• Grondin R, Kaytor MD, Ai Y, et al. Six-month partial suppression of huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012;135(Pt 4):1197–1209.
   PubMedGoogle Scholar
• Kaplan A, Stockwell BR. Therapeutic approaches to preventing cell death in Huntington disease. Prog Neurobiol. 2012;99(3):262–280.
   PubMed Web of Science ®Google Scholar
• Yu D, Pendergraff H, Liu J, et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 2012;150(5):895–908.
   PubMed Web of Science ®Google Scholar
• Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clin Genet. 2014;86(1):29–36.
   Web of Science ®Google Scholar
• Papworth M, Kolasinska P, Minczuk M. Designer zinc-finger proteins and their applications. Gene. 2006;366(1):27–38.
   PubMed Web of Science ®Google Scholar
• Garriga-Canut M, Agustín-Pavón C, Herrmann F, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A. 2012;109(45):E3136–E3145.
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Sutton L, Hayden MR. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist. 2011;17(5):475–492.
   Google Scholar
• Ehrnhoefer DE, Duennwald M, Markovic P, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington’s disease models. Hum Mol Genet. 2006;15(18):2743–2751.
   PubMed Web of Science ®Google Scholar
• Smith MR, Syed A, Lukacsovich T, et al. A potent and selective sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington’s disease. Hum Mol Genet. 2014;23(11):2995–3007.
   PubMed Web of Science ®Google Scholar
• Süssmuth S, Landwehrmeyer G, Tabrizi S, et al. A randomised, double-blind, placebo-controlled phase IB pharmacodynamic study with selisistat (SEN0014196) in HD patients. J Neurol Neurosurg Psychiatry. 2012;83(Suppl 1):A55.
   Google Scholar
• Reilmann R, Squitieri F, Priller J, et al. Safety and tolerability of selisistat for the treatment of Huntington’s disease: results from a randomized, double-blind, placebo-controlled phase II trial. Neurology. 2014;82(Suppl 10):S47.004.
   Google Scholar
• Labbadia J, Novoselov SS, Bett JS, et al. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain. 2012;135(Pt 4):1180–1196.
   Google Scholar
• Butler DC, McLear JA, Messer A. Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog Neurobiol. 2012;97(2):190–204.
   Web of Science ®Google Scholar
• Leavitt BR, Guttman JA, Hodgson JG, et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet. 2001;68(2):313–324.
   PubMed Web of Science ®Google Scholar
• Mugat B, Parmentier ML, Bonneaud N, Chan HY, Maschat F. Protective role of engrailed in a Drosophila model of Huntington’s disease. Hum Mol Genet. 2008;17(22):3601–3616.
   Web of Science ®Google Scholar
• Bonneaud N, Paucard A, Bauer C, et al. Systemic delivery of P42 peptide to fight Huntington’s disease. J Neurol Neurosurg Psych. 2014;85(Suppl 1):A98.
   Google Scholar
• Marelli C, Bonneaud N, Paucard A, Maschat F. Efficacy of the peptide P42B in HeLa cells and in the HD Drosophila model. J Neurol Neurosurg Psych. 2014;85(Suppl 1):A97.
   Google Scholar
• Coskran TM, Morton D, Menniti FS, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem. 2006;54(11):1205–1213.
   PubMed Web of Science ®Google Scholar
• Gines S, Seong IS, Fossale E, et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet. 2003;12(5):497–508.
   Web of Science ®Google Scholar
• Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008;325(2):681–690.
   PubMed Web of Science ®Google Scholar
• Grauer SM, Pulito VL, Navarra RL, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009;331(2):574–590.
   PubMed Web of Science ®Google Scholar
• Siuciak JA, Chapin DS, Harms JF, et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006;51(2):386–396.
   Web of Science ®Google Scholar
• Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A. 2000;97(12):6763–6768.
   PubMed Web of Science ®Google Scholar
• Kleiman RJ, Kimmel LH, Bove SE, et al. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington’s disease. J Pharmacol Exp Ther. 2011;336(1):64–76.
   PubMed Web of Science ®Google Scholar
• Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology. 2006;51(2):374–385.
   PubMed Web of Science ®Google Scholar
• Giampa C, Patassini S, Borreca A, et al. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington’s disease. Neurobiol Dis. 2009;34(3):450–456.
   Web of Science ®Google Scholar
• Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington’s disease. PLoS One. 2010;5(10):e13417.
   PubMed Web of Science ®Google Scholar
• Giralt A, Saavedra A, Carreton O, et al. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington’s disease mouse model. Hippocampus. 2013;23(8):684–695.
   PubMed Web of Science ®Google Scholar
• Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s disease transgenic mice prior to the onset of motor symptoms. Neuroscience. 2004;123(4):967–981.
   Web of Science ®Google Scholar
• Ahmad R, Bourgeois S, Postnov A, et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology. 2014;82(3):279–281.
   PubMed Web of Science ®Google Scholar
• Benchoua A, Trioulier Y, Zala D, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell. 2006;17(4):1652–1663.
   PubMed Web of Science ®Google Scholar
• Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41(5):646–653.
   PubMed Web of Science ®Google Scholar
• Kim J, Moody JP, Edgerly CK, et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet. 2010;19(20):3919–3935.
   PubMed Web of Science ®Google Scholar
• Costa V, Scorrano L. Shaping the role of mitochondria in the pathogenesis of Huntington’s disease. EMBO J. 2012;31(8):1853–1864.
   PubMed Web of Science ®Google Scholar
• Hyson HC, Kieburtz K, Shoulson I, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington’s disease and healthy subjects. Mov Disord. 2010;25(12):1924–1928.
   Web of Science ®Google Scholar
• Sunyach C, Michaud M, Arnoux T, et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology. 2012;62(7):2346–2352.
   PubMed Web of Science ®Google Scholar
• Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014;21(3):529–536.
   PubMed Web of Science ®Google Scholar
• Eckmann J, Clemens LE, Eckert SH, et al. Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime. Mol Neurobiol. 2014;50(1):107–118.
   Web of Science ®Google Scholar
• Clemens L, Weber J, Wlodkowski TT, et al. Olesoxime treatment inhibits the formation of mHtt fragments through suppression of calpain activity, and leads to behavioral and neurological improvements in the BACHD rat. J Neurol Neurosurg Psych. 2014;85(Suppl 1):A62.
   Google Scholar
• Hands SL, Mason R, Sajjad MU, Giorgini F, Wyttenbach A. Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington’s disease. Biochem Soc Trans. 2010;38(2):552–558.
   Google Scholar
• Chernya R, Aytona S, Finkelsteina D, Busha A, McColla G, Massac S. PBT2 reduces toxicity in a C. elegans model of polyQ aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6/2 mouse model of Huntington’s disease. J Huntingtons Dis. 2012;1(2):211–219.
   Google Scholar
• Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIA, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7(9):779–786.
   PubMed Web of Science ®Google Scholar
• Sampaio C, Borowsky B, Reilmann R. Clinical trials in Huntington’s disease: interventions in early clinical development and newer methodological approaches. Mov Disord. 2014;29(11):1419–1428.
   PubMed Web of Science ®Google Scholar
• Vécsei L, Szalárdy L, Fülöp F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2013;12(1):64–82.
   PubMed Web of Science ®Google Scholar
• Zwilling D, Huang SY, Sathyasaikumar KV, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145(6):863–874.
   PubMed Web of Science ®Google Scholar
• Björkqvist M, Wild EJ, Thiele J, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med. 2008;205(8):1869–1877.
   PubMed Web of Science ®Google Scholar
• Träger U, Andre R, Lahiri N, et al. HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation. Brain. 2014;137(Pt 3):819–833.
   PubMedGoogle Scholar
• Brück W, Pförtner R, Pham T, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012;124(3):411–424.
   PubMed Web of Science ®Google Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000–1009.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry. 2014;85(8):851–858.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington’s disease since 1990. Expert Opin Pharmacother. 2007;8(2):141–153.
   PubMed Web of Science ®Google Scholar
• Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An International survey-based algorithm for the pharmacologic treatment of chorea in Huntington’s disease. PLoS Curr. 2011;3:RRN1260.
   Google Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366–372.
   PubMed Web of Science ®Google Scholar
• Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31(3):127–133.
   PubMed Web of Science ®Google Scholar
• HORIZON Investigators of the Huntington Study Group and European Huntington’s Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. Arch Neurol. JAMA Neurol. 2013;70(1):25–33.
   Web of Science ®Google Scholar
• de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD):a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049–1057.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease. Mov Disord. 2013;28(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• Kosinski CM, Schlangen C, Gellerich FN, et al. Myopathy as a first symptom of Huntington’s disease in a marathon runner. Mov Disord. 2007;22(11):1637–1640.
   Google Scholar
• Zielonka D, Piotrowska I, Marcinkowski JT, Mielcarek M. Skeletal muscle pathology in Huntington’s disease. Front Physiol. 2014;5:380.
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Rattray I, Osborne G, et al. Myostatin inhibition as a novel approach to targeting muscle pathology in HD. J Neurol Neurosurg Psych. 2014;85(Suppl 1):A97.
   Google Scholar